Basic information in vivo Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Respiratory Drugs >  Asthma drugs >  FENOTEROL HYDROBROMIDE

FENOTEROL HYDROBROMIDE

Basic information in vivo Safety Supplier Related

FENOTEROL HYDROBROMIDE Basic information

Product Name:
FENOTEROL HYDROBROMIDE
Synonyms:
  • FENOTEROL HBR
  • FENOTEROL HYDROBROMIDE
  • 2-[3,5-DIHYDROXYPHENYL]-2-HYDROXY-2'-[4-HYDROXYPHENYL]-1'-METHYLDIETHYLAMINE HYDROBROMIDE
  • 1-(3,5-dihydroxy-phenyl)-2-((1-(4-hydroxybenzyl)ethyl)amino)-ethanolhydrobro
  • berotec
  • berotechydrobromide
  • fenoterolbromide
  • partusisten
CAS:
1944-12-3
MF:
C17H22BrNO4
MW:
384.26
EINECS:
217-742-8
Product Categories:
  • Amines
  • Aromatics
  • Adrenoceptor
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
Mol File:
1944-12-3.mol
More
Less

FENOTEROL HYDROBROMIDE Chemical Properties

Melting point:
226-228°C
storage temp. 
2-8°C
solubility 
Soluble in water and in ethanol (96 per cent).
color 
White to Off-White
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22
Safety Statements 
36
RIDADR 
3249
WGK Germany 
3
RTECS 
DO1500000
HazardClass 
6.1(b)
PackingGroup 
III
HS Code 
29225090
Toxicity
LD50 in mice (mg/kg): 1100 s.c.; 1990 orally (Goldenthal)

MSDS

More
Less

FENOTEROL HYDROBROMIDE Usage And Synthesis

in vivo

Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.

Chemical Properties

White Solid

Originator

Berotec,Boehringer Ingelheim,W. Germany,1972

Uses

An β2-adrenergic agonist. Bronchodilator; tocolytic.

Definition

ChEBI: The hydrobromide salt of fenoterol. A beta2-adrenergic agonist, it is used as a bronchodilator in the management of reversible airway obstruction.

Manufacturing Process

441 grams (1.4 mols) of 3,5-diacetoxy-α-bromo-acetophenone (MP 66°C), prepared by bromination of 3,5-diacetoxy-acetophenone, were added to a solution of 714 grams (2.8 mols) of 1-p-methoxyphenyl-2-benzylaminopropane in 1,000 cc of benzene, and the resulting solution mixture was refluxed for 1 hour. The molar excess of 1-p-methoxy-phenyl-2-benzylaminopropane precipitated out as its hydrobromide. After separation of the precipitated hydrobromide of the amino component, the hydrochloride of 1-pmethoxy- phenyl-2-(β-3',5'-diacetoxyphenyl-β-oxo)-ethyl-benzylamino-propane was precipitated from the reaction solution by addition of an ethanolic solution of hydrochloric acid. The precipitate was separated and, without further purification, was deacetylated by boiling it in a mixture of 2 liters of aqueous 10% hydrochloric acid and 1.5 liters of methanol.
The resulting solution was filtered through animal charcoal and, after addition of 2 liters of methanol, it was debenzylated by hydrogenation at 60°C over palladinized charcoal as a catalyst. After removal of the catalyst by filtration, the filtrate was concentrated by evaporation, whereupon the hydrochloride of 1-p-methoxyphenyl-2-(β-3',5'-dihydroxyphenyl-β-oxo)-ethylamino-propane (MP 244°C) crystallized out. For the purpose of demethylation, the 350 grams of the hydrochloride thus produced were refluxed for 2 hours with 3.5 liters of aqueous 48% hydrobromic acid. Upon cooling of the reaction solution, 320 grams of 1-p-hydroxyphenyl-2-(β-3',5'-dihydroxyphenyl-β-oxo)-ethylaminopropanehydrobromide (MP 220°C) crystallized out.
·220 grams of 1-p-hydroxyphenyl-2-(β-3',5'-dihydroxyphenyl-β-oxo)- ethylamino-propane hydrobromide were dissolved in 1 liter of methanol, the resulting solution was boiled with activated charcoal, the charcoal was filtered off and the filtrate was hydrogenated in the presence of Raney nickel at 60°C and 5 atmospheres gauge. Thereafter, the catalyst was filtered off, the methanolic solution was admixed with a small amount of concentrated hydrobromic acid, and the mixture was evaporated to dryness in vacuo. The residue was stirred with acetone, the mixture was vacuum filtered and the filter cake was recrystallized from a mixture of methanol and ether. The 1-phydroxyphenyl- 2-(β-3',5'-dihydroxyphenyl-β-hydroxy)-ethylamino-propane hydrobromide thus obtained had a melting point of 222° to 223°C.

Therapeutic Function

Bronchodilator

Clinical Use

Fenoterol is an investigational drug in the United States that has been in use in Europe since 1970. It is the p-hydroxyphenyl derivative of metaproteronol, and the combination of the resorcinol ring and the bulky p-hydroxyphenyl isopropyl group on the nitrogen gives fenoterol significant β2-receptor selectivity. It has approximately half the affinity for the β2-receptor as compared to albuterol. The resorcinol ring is resistant to COMT metabolism, and the bulky nitrogen substituent greatly retards MOA metabolism as well giving fenoterol a reasonable oral bioavailability with pharmacokinetics similar to albuterol (i.e., rapid onset and a 4- to 6-hour duration of action after oral inhalation).

FENOTEROL HYDROBROMIDESupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com